DarDoc Research

GLP-1 Trial & Approval Tracker

Compare GLP-1 trial arms

Compare results within a trial or inspect the context behind results from different studies.

ATTAIN-2

Foundayo

With type 2 diabetes · 72 weeks · n=1,613

Double-blind, placebo-controlled. Treatment-regimen analysis. Orforglipron was studied as capsules.

Mean body weight change at 72 weeks
  • Orforglipron 6 mg−5.1%
  • Orforglipron 12 mg−7.0%
  • Orforglipron 36 mg−9.6%
  • Placebo−2.5%
Published paper PubMed abstract NCT05872620

A direct comparison uses arms from the same trial. Switch to Two studies to inspect the context behind separate results.